Aeglea BioTherapeutics News - AGLE

Company Name	Stock Ticker Symbol	Market	Type
Aeglea BioTherapeutics Inc	AGLE	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.00	0.00%	12.01	20:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
			12.01	12.01

more quote information »

Recent News

Date	Time	Source	Heading
4/02/2024	16:36	EDGAR2	Form ARS - Annual Report to Security Holders
4/01/2024	16:06	EDGAR2	Form DEF 14A - Other definitive proxy statements
3/20/2024	07:14	EDGAR2	Form PRE 14A - Other preliminary proxy statements
3/18/2024	16:06	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
3/18/2024	08:31	EDGAR2	Form 8-K - Current report
3/14/2024	16:12	EDGAR2	Form POS AM - Post-Effective amendments for registration..
11/28/2023	16:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/28/2023	07:33	EDGAR2	Form 8-K - Current report
11/27/2023	16:36	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/27/2023	16:33	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/27/2023	16:32	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
11/27/2023	16:27	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
11/27/2023	16:25	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/27/2023	08:30	PRNUS	Aeglea BioTherapeutics Announces Name Change to Spyre..
11/22/2023	20:45	EDGAR2	Form 8-K - Current report
11/22/2023	17:00	PRNUS	Aeglea BioTherapeutics Announces Grants of Inducement Awards
11/15/2023	17:18	EDGAR2	Form S-1/A - General form for registration of securities..
11/15/2023	17:14	EDGAR2	Form 8-K - Current report
11/14/2023	15:13	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
11/09/2023	16:10	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/2023	16:06	EDGAR2	Form 8-K - Current report
11/09/2023	16:05	PRNUS	Aeglea BioTherapeutics Reports Third Quarter 2023 Financial..
11/03/2023	17:00	PRNUS	Aeglea BioTherapeutics Announces Grants of Inducement Awards
10/30/2023	20:00	PRNUS	Aeglea BioTherapeutics to Participate in Upcoming November..
10/26/2023	21:53	EDGAR2	Form DEF 14A - Other definitive proxy statements
10/24/2023	09:00	EDGAR2	Form 8-K - Current report
10/06/2023	21:40	EDGAR2	Form PRER14A - Preliminary Proxy Soliciting materials
10/05/2023	17:13	EDGAR2	Form 8-K - Current report
10/02/2023	18:02	PRNUS	Aeglea BioTherapeutics Announces Grants of Inducement Awards
9/25/2023	16:02	EDGAR2	Form 8-K - Current report
9/14/2023	17:03	PRNUS	Aeglea BioTherapeutics to Participate in Upcoming September..
9/08/2023	17:05	EDGAR2	Form 8-K - Current report
9/07/2023	08:40	PRNUS	Aeglea BioTherapeutics Announces Reverse Stock Split
9/05/2023	16:15	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/05/2023	16:10	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
9/05/2023	16:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/05/2023	16:06	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
9/05/2023	07:06	EDGAR2	Form 8-K - Current report
9/05/2023	07:00	PRNUS	Aeglea BioTherapeutics Expands Executive Leadership Team..
8/11/2023	07:07	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/11/2023	07:02	EDGAR2	Form 8-K - Current report
8/11/2023	07:01	EDGAR2	Form 8-K - Current report
8/11/2023	07:00	PRNUS	Aeglea BioTherapeutics Reports Second Quarter 2023 Financial..
8/07/2023	21:51	EDGAR2	Form PRE 14A - Other preliminary proxy statements
8/07/2023	16:25	EDGAR2	Form S-3 - Registration statement under Securities Act of..
7/28/2023	09:01	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
7/27/2023	07:01	EDGAR2	Form 8-K - Current report
7/27/2023	07:00	PRNUS	Aeglea BioTherapeutics Announces Sale of Pegzilarginase to..
7/18/2023	16:01	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
7/14/2023	16:05	EDGAR2	Form 8-K - Current report